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Abstract
Purpose. To make recommendations for the use of doxorubicin-based chemotherapy in patients with soft-tissue sarcoma.
Patients. The recommendations apply to patients with symptomatic unresectable locally advanced or metastatic soft-tissue
sarcoma who are candidates for palliative chemotherapy.
Methods. A systematic review of the published literature was combined with a consensus process around the interpretation
of the evidence in the context of conventional practice to develop an evidence-based practice guideline.
Results. Eight randomized trials comparing doxorubicin-based combination versus doxorubicin single-agent chemotherapy
were reviewed.Response rates and overall survival were evaluated using pooled statistical analysis.The pooled response data
in 2281 patients showed a slight trend favouring the combination therapy, although this did not reach statistical signi® cance
(odds ratio (OR), 0.79; 95% con® dence interval (CI), 0.60± 1.05; p=0.10). Survival data could only be abstracted from six
studies involving 2097 patients, and showed no signi® cant advantage for combination therapy (OR, 0.84; 95% CI, 0.67±
1.06; p=0.13). Data on adverse effects could not be combined in a meta-analysis; however nausea, vomiting and myelosup-
pression were consistently more severe with combination chemotherapy than with single-agent chemotherapy.
Discussion. Single-agentdoxorubicin is an appropriate ® rst-line chemotherapy option for advanced or metastatic soft-tissue
sarcoma.Some doxorubicin-based combinationchemotherapy regimens,givenin conventionaldoses,produce only marginal
increases in response rates, at the expense of increased adverse effects, and with no improvements in overall survival. Future
randomized clinical trials should compare new regimens, whose activity has been established in single-arm studies, with
single-agent doxorubicin,and include quality of life as an outcome measure.
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Introduction
Doxorubicin was ® rst identi® ed as an active agent in
the treatment of adult soft-tissue sarcomas in the
1970s, and response rates in early studies ranged
from 9% to 70%.
1 More recently, large randomized
multi-centre studies have established response rates
in the range of 16± 27% for single-bolus doses of
doxorubicin given every 3 weeks.
2± 9 Subsequently,
dacarbazine (DTIC) and ifosfamide were identi® ed
as active agents, with single-agent response rates of
18% for dacarbazine,
10 and 18± 36% for
ifosfamide.
11± 13 A large number of other evaluated
drugs have been shown to have minimal or
inconsistent activity in patients with soft-tissue
sarcomas.
14
Variouscombinationsof the active drugshave been
evaluated in a number of non-randomized stud-
ies,
14,15with documentedresponserates in the range
of 35± 60%, but generally at the expense of greater
toxicity. Combination chemotherapy regimens not
containingdoxorubicinhave consistentlyyielded poor
results in adult patients with advanced soft-tissue
sarcoma.
3,16,17 Results from large randomized
studies,
2± 9 comparing doxorubicin-based combina-
tion chemotherapy regimens with single-agent doxo-
rubicin, have been more varied. In some of these
trials,responserates have been higherin the combina-
tion chemotherapy arms, whereas in others primary
outcomes have not been signi® cantly different
between the treatments.
4,7,9
Thus, there is considerable controversy as to
whether any added bene® t of combination
chemotherapy outweighs increased toxic effects and
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to health care systems.This has led to a substantial
variation in clinical practice. The Sarcoma Disease
Site Group(DSG) felt that a practice guideline,based
on an unbiased, systematic review of the evidence,
was warranted.The guideline was developed speci® -
cally to answer the following questions.
1. Is there an advantage, in terms of response rate or
survival, in using doxorubicin-based combination
chemotherapy compared with single-agent doxo-
rubicin for the palliative treatment of patients with
incurable locally advanced or metastatic soft-
tissue sarcoma?
2. Is combination chemotherapy associated with
increased toxic effects compared with single-agent
doxorubicin in this setting?
Patients
This practice guideline addressed the treatment of
patients with locally advanced or metastatic soft-
tissue sarcoma who are candidates for palliative
chemotherapy. Some patients with locally advanced
soft-tissue sarcomas may be surgical candidates, and
multi-disciplinaryconsultation between a specialized
sarcoma surgeon, a radiation oncologist, a medical
oncologist, a radiologist and a pathologist should be
undertaken to determinethe optimal managementof
these cases. A selected group of patients with metas-
tases con® ned to the lungs (and rarely at other sites)
may be suitable for resection with curative intent,
18,19
and this option should be considered prior to the use
of palliative chemotherapy.
Methods
Literature search strategy
MEDLINE (Ovid) (from 1966) and CANCERLIT
(Ovid)(from 1975) were searched in December1997.
`Doxorubicin’ (MeSH term and text word) was
combined with `combin’ (truncated text word) and
`sarcoma’ (MeSH term and text word), and these
terms were then combined with search terms for the
followingstudydesigns:practice guidelines;systematic
reviews or meta-analysis; and randomized controlled
trials.This search was updated inApriland December
1998, June 1999 and January 2000. EMBASE was
also searched from 1979 to 1995 using the truncated
keywords `random’ and `sarcoma’. Citation lists and
personal ® les were scanned for additional studies. In
addition, the Proceedings of the Annual Meeting of the
American Society of Clinical Oncology (1995± 99), and
the Cochrane Library (issue 4, 1999), were also
searched for additional reports of newly completed
trials.No further attempt was made to ® nd reports of
unpublished randomized controlled trials. Relevant
articles and abstracts were selected and assessed by
two reviewers and the reference lists from these
sources were searched for additional trials.
Study selection
For a study to be eligible, it had to be a randomized
controlled trial comparing single-agent doxorubicin
with a doxorubicin-basedcombinationchemotherapy
regimen, and involve adult patients with locally
advanced or metastatic soft-tissue sarcoma in the
palliative setting. Potential studies had to measure
response rate, overall survival and toxic effects or
quality of life.
Pooling of trial results
The intent was to combine (i.e. pool) data from all
eligible trials, in order to calculate overall estimates
of treatment efficacy and harm. Pooled results were
expressed as an odds ratio (OR), which is the odds of
an event occurring in the experimental group over
the odds of an event occurring in the control group,
with a 95% con® dence interval (CI). Target events
were consistently unfavourable (e.g. death at 2 years,
nocompleteor partial response,etc.),so that estimates
greater than 1.0 favoured the control group (single-
agent therapy) and estimates less than 1.0 favoured
the experimental group (combination therapy). The
more conservative random effects model was used in
the meta-analyses to allow for the differences in trial
design and quality.
20 A statistical Q-test was used to
measure the quantitative heterogeneity among study
results. Calculations for the meta-analysis were
performed on a Pentium PC using the software
program Metaanalyst
0.988, created by Dr Joseph Lau
(Boston, MA).
Guideline development process
The guideline was developed out of the Cancer Care
Ontario Practice Guidelines Initiative, using the
methodology of the Practice Guidelines Develop-
ment Cycle by Browman et al.
21 The guideline is a
convenient and up-to-date source of the best avail-
able evidence on the use of doxorubicin-based
chemotherapy for the palliative treatment of locally
advanced or metastatic soft-tissue sarcoma. It has
been developed through systematic reviews, evidence
synthesis and input from practitioners in Ontario,
Canada. It is intended to enable evidence-based
practice.
Practitioner feedback was obtained through a
mailed survey consisting of questions asking for
ratings on the quality of the evidence-based recom-
mendation (EBR) and whether the EBR should serve
as a practice guideline.
Results
Literature search results
There were eight randomized controlled trials identi-
® ed which met the eligibility criteria,
2± 9 comparing
104 V .H.C.Bramwell et al.doxorubicin combination chemotherapy with single-
agent doxorubicin.Trialcharacteristics,includingthe
chemotherapy regimens, are shown in Table 1.
Outcome measures across all eight trials included
responserates,median survival and various measures
of toxicity, and these are shown in Tables 2 and 3.
Response duration and time-to-progression were not
reported consistently across studies and could not be
analysed further. There were no practice guidelines
or systematic reviews identi® ed in theliteraturesearch.
Table 1. Randomized controlled trials of doxorubicin combination chemotherapy in adult patients with incurable locally
advanced or metastatic soft-tissue sarcoma
Study Tumour type Chemotherapy Regimens*
Randomized
patients
(evaluable)²
Chang &Wiernik,
2 1976,
NCI (USA)
Adult STS
(4 bone sarcomas)
4 prior chemo
DOX
DOX
STREPT
60 mg/m
2 IV bolus
60 mg/m
2 IV bolus
500 mg/m
2 IV bolus days
1± 5
18 (17)
15 (14)
Schoenfeld et al.,
3 1982² ,
ECOG
Adult STS
(18 bone
sarcomas,
9 mesotheliomas)
3 prior chemo
DOX
DOX
VCR
CYCLO
70 mg/m
2 IV bolus
50 mg/m
2 IV bolus
1.4 mg/m
2 IV bolus
750 mg/m
2 IV bolus
71 (66)
80 (70)
Omura et al.,
4 1983,
GOG
Uterine sarcomas
31 prior chemo
DOX
DOX
DTIC
60 mg/m
2 IV bolus
60 mg/m
2 IV bolus
250 m/m
2 IV bolus days 1± 5
155 (120)
160 (106)
Muss et al.,
5 1985,
GOG
Uterine sarcomas DOX
DOX
CYCLO
60 mg/m
2 IV bolus
60 mg/m
2 IV bolus
500 mg/m
2 IV bolus
66 (50)
66 (54)
Borden et al.,
6 1987,
ECOG
Adult STS DOX
DOX
DOX
DTIC
70 mg/m
2 IV bolus
20 mg/m
2 days 1± 3 IV bolus
then 15 mg/m
2/week
60 mg/m
2 IV bolus
250 mg/m
2 IV bolus days
1± 5
123 (94)
119 (88)
119 (92)
Borden et al.,
7 1990,
ECOG
Adult STS DOX
DOX
VND
70 mg/m
2 IV bolus
70 mg/m
2 IV bolus
3 mg/m
2 IV bolus
176 (151)
171 (147)
Edmonson et al.,
8 1993,
ECOG
Adult STS
(4 bone sarcomas)
DOX
DOX
IFOS
DOX
MITC
DDP
80 mg/m
2 IV bolus
60 mg/m
2 IV bolus
3.75 g/m
2 IV 4 h 3 2 days
40 mg/m
2 IV bolus
8 mg/m
2 IV bolus
60 mg/m
2 IV bolus
95 (90)
94 (88)
90 (84)
Santoro et al.,
9 1995,
EORTC
Adult STS DOX
DOX
VCR
CYCLO
DTIC
DOX
IFOS
75 mg/m
2 IV bolus
50 mg/m
2 IV bolus
1.5 mg/m
2 IV bolus
500 mg/m
2 IV bolus
750 mg/m
2 IV 30 minutes
50 mg/m
2 IV bolus
5 g/m
2 IV 24 h
263 (240)
142 (134)
258 (231)
NCI = National Cancer Institute; ECOG = Eastern Cooperative Oncology Group; GOG = Gynecologic Oncology Group;
EORTC = European Organization for Research andTreatment of Cancer; STS = soft-tissue sarcoma; DOX = doxorubicin;
STREPT = streptozotocin; VCR = vincristine; CYCLO = cyclophosphamide; DTIC = dacarbazine; VND = vindesine;
IFOS = ifosfamide; MITC = mitomycin; DDP = cisplatin; IV = intravenous.
*All doses are given every 3 weeks unless stated otherwise.
² Third arm: vincristine, actinomycin D, cyclophosphamide.
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Therewere nine single-agentdoxorubicinarms (1086
total patients entered) in the eight studies.One study
evaluated doxorubicin given in two different
schedules.
6 Each study included an arm in which
high-dose single-agentdoxorubicinwas given every 3
weeks. In three studies,
2,4,5 the dose was 60 mg/m
2;
in three studies,
3,6,770 mg/m
2;one study used a dose
of 75 mg/m
2;
9and a ® nal study used a dose of 80 mg/
m
2.
8 In one study,
6 there was an additional arm in
which doxorubicin(20 mg/m
2 3 3) was administered
as a loading dose followed by 15 mg/m
2 weekly.
There were 10 doxorubicin-based combination
chemotherapy regimens given in eight studies (1195
total patients entered). The dose of doxorubicin in
combination with other agents was 40 mg/m
2 in one
study,
8 50 mg/m
2 in two studies,
3,9 60 mg/m
2 in ® ve
studies,
2,4± 6,8 and 70 mg/m
2 in one study;
7 in each
case treatment was repeated every 3 weeks. The
doxorubicin-based combination chemotherapy
regimens included doxorubicin with either vindes-
ine,
7streptozotocin,
2or cyclophosphamide;
5doxoru-
bicin with ifosfamide in two studies;
8,9 doxorubicin
with DTIC in two studies;
4,6 doxorubicin with
mitomycin-C and cisplatin in one study;
8 doxoru-
bicin with vincristine and cyclophosphamide in one
study;
3 and doxorubicin with vincristine, cyclophos-
phamide and DTIC in one study.
9
Although a few patients who had received previous
chemotherapy (Table 1) were included in the earlier
studies,
2± 4 most patients were chemotherapy-naive
when they entered these studies. Similarly, the
majority had adult soft-tissue sarcoma, although a
few bonesarcomasand mesotheliomas were included
in three studies.
2,3,8 All the trials excluded some
patients entered on study who were subsequently
Table 2. Response rates and median survival times reported in randomized trials of doxorubicin chemotherapy*
Study Treatment
No. of evaluable
patients
No. of responders
(%)
Median survival
(months)
Chang &Wiernik,
2
1976
DOX 17 4 (24) 10.2
DOX + STREPT 14 2 (14) 10.6
(p=NS)
Schoenfeld et al.,
3
1982
DOX 66 18 (27) 8.5
DOX + VCR + CYCLO 70 13 (19) 7.8
(p=0.03)²
Omura et al.,
4
1983
DOX 120 13/80 (16) 7.7
DOX + DTIC 106 16/66 (24) 7.3
(p=NS)
Muss et al.,
5
1985
DOX 50 5/26 (19) 11.6
DOX + CYCLO 54 5/26 (19) 10.9
(p=NS)
Borden et al.,
6
1987
DOX every 3 weeks 94 17 (18) 8.0
DOX loading every week 88 15 (17) 8.4
DOX + DTIC 92 28 (30) 8.0
(p=0.03)‡
Borden et al.,
7
1990
DOX 151 26 (17) 9.4
DOX + VND 147 26 (18) 9.9
(p=NS)
Edmonsen et al.,
8
1993
DOX 90 18 (20) 8.4
DOX + IFOS 88 30 (34) 11.5
DOX + MITC + DDP 84 27 (32) 9.4
(p=0.03)‡
Santoro et al.,
9
1995
DOX 240 56 (23) 12.0
DOX + VCR + CYCLO
+ DTIC
134 38 (28) 11.8
DOX + IFOS 231 65 (28) 12.7
(p=NS)
*Abbreviations are explained in the ® rst footnote toTable 1; NS = not signi® cant.
² Single-agent doxorubicin better than combination chemotherapy.
‡ Doxorubicin combination chemotherapy better than single-agent doxorubicin.
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patients were found not to be evaluable for response
(Table 1).
Table 2 outlinesresponserates and mediansurvival,
which were consistently reported across all studies.
Response rates for single-agent doxorubicin ranged
between 16% and 27%. Response rates for combina-
tion chemotherapy ranged from a low of 14% for
doxorubicinand streptozotocin,
2to 34% for doxoru-
bicin and ifosfamide.
8 Response rates were
signi® cantly better for the combinationchemotherapy
regimens in only two trials. In one study,
6 the
combination of doxorubicin and DTIC was superior
to doxorubicin (p=0.03), given by two different
schedules,and in the second study,
8the combination
of doxorubicinand ifosfamide was superiorto single-
agent doxorubicin (p=0.03). In one study,
3 response
rate was signi® cantly better on doxorubicincompared
with the combination of doxorubicin,vincristine and
cyclophosphamide (p=0.03). None of the studies
showed any signi® cant differences in median survival
time between single-agentdoxorubicinand combina-
tion chemotherapy.
Assessment of trial quality
Studies included in this systematic overview were
published between 1976 and 1995. In general, later
reports included more details about methodology,
particularly statistical analysis.Five studies described
a satisfactory (central office) method of
randomization,
3,6± 9 and four studies included an
outline of statistical methodology in the `Patient’/
`Materials and methods’ section.
4,6,7,9 However, in
only two papers were accrual goals set and met.
7,9
The studiesconductedby Chang &Wiernikand Muss
et al. were of inadequate size to properly evaluate
differences in response rate or survival.
2,5 Although
response criteria were described or referenced in all
except one study,
3 it is generally accepted that the
Table 3. Toxic effects reported in randomized trials of doxorubicin chemotherapy*
Study Treatment Toxic effect
Nausea and vomiting White blood cell count Platelet count
Chang &Wiernik,
2 WBC <2000 PLATS <100 000
1976 DOX 59% mild/moderate 9% 3%
DOX + STREPT 100% moderate/severe 30% 13%
(p<0.01) (p<0.03)
Schoenfeld et al.,
3 Haematologic
1982 DOX 42% moderate/severe 17% severe
DOX + VCR + CYCLO 60% moderate/severe 30% severe
(p=0.09) (p=0.07)
Omura et al.,
4 Grade 3/4 Grade 3/4 Grade 3/4
1983 DOX 2.2% 16% 4%
DOX + DTIC 8.5% 35% 13%
Muss et al.,
5 WBC <2000 PLATS <50 000
1985 DOX 0% severe 10% 0%
DOX + CYCLO 6% severe 35% 0%
Borden et al.,
6 Haematologic
1987 DOX every 3 weeks 11% severe 28% severe
DOX loading every week 6% severe 13% severe
DOX + DTIC 29% severe 29% severe
(p=0.000 03) (p=0.87)
Borden et al.,
7 Haematologic
1990 DOX 6% severe 36% severe
DOX + VND 3% severe 50% severe
Edmonson et al.,
8 Haematologic
1993 DOX 7% severe 53%
DOX + IFOS 18% severe 80%
DOX + MITC + DDP 17% severe 55%
(p=0.01)
Santoro et al.,
9 Grade 3/4 Grade 4 Grade 3/4
1995 DOX 17% 13% 4%
DOX + VCR + CYCLO
+ DTIC
40% 15% 10%
DOX + IFOS NR 32% 6%
(p<0.001)
*Abbreviations are explained in the ® rst footnote to Table 1; NR = not reported; WBC = white blood cells; PLATS =
platelets.
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the past 20 years becauseof better imagingtechniques
and attention to quality-control procedures. Thus,
the results reported in later studies may be more reli-
able.Two papers provided very limited data on toxic
effects,
3,4 and only two papers provided detailed
tabular reports of toxic effects seen in multiple
systems.
7,9 In ® ve studies,
4,6± 8 central pathology
review was performedin a majority of tumours.Some
analysis of delivered dose of relevant drugs was
performed in four studies.
5,6,8,9
Overall, it was not felt that there were a sufficient
number of papers, in which the quality exceeded the
remainder, to justify a sensitivity analysis based on
quality.However,a sensitivity analysis was performed
on the four trials that included a combination of
doxorubicin with at least one of the other known
active agents for soft-tissue sarcoma (i.e. ifosfamide
and DTIC) in their regimens.
4,6,8,9
Meta-analysis results
Data were combined for objective tumour response
and overall survival. A statistical Q-test showed no
signi® cant numerical heterogeneity across studies for
these two outcomes.The Q-test values were 9.45 for
objective tumour response and 3.42 for overall
survival. Adverse effects data were not combined, as
the outcomes and measures varied greatly among
studies.
Objective tumour response. Objective tumour response
(completeand partial) data were available and consist-
ently reported in all eight trials, providing eight
comparisons with a total of 2281 patients.The trials
ranged in size from 663 randomized patients,
9 to 33
randomized patients.
2 Results of pooling response
data (Fig. 1) showed a slight trend favouring the
combination therapy, though this did not reach
statistical signi® cance (OR, 0.79; 95% CI, 0.60±
1.05; p=0.10). However, when the data pooling was
restricted to the four trials involving combination
regimens of known active agents,
4,6,8,9 this trend
disappeared (OR, 0.71; 95 CI, 0.45± 1.13; p=0.15).
Overall survival. Survival data were extracteddirectly
from probability graphs for six of the eight trials, for
a total of 2097 patients. In two trials, survival data
either were not reported,
2or could not be extracted.
3
Trial size ranged from 663 randomized patients,
9 to
132 randomized patients.
5 Results of pooling this
outcome measure across six studies (Fig. 2) were not
statistically signi® cant (OR, 0.84; 95% CI, 0.67±
1.06; p=0.13), and the results did not signi® cantly
change when the data were restricted to the four
trials usingcombinationsof known active agents (OR,
0.90; 95% CI, 0.69± 1.20; p=0.48).
4,6,8,9
Epirubicin. Consideration was given to broadening
the guideline to include any randomized studies of
single-agent anthracycline versus the same anthracy-
cline in combination with other agents. Epirubicin
has been evaluated as a single agent in two European
Organization for Research and Treatment of Cancer
(EORTC) randomized trials,
22,23 as well as in a
number of single-arm combination chemotherapy
studies. In the second EORTC study,
23 high-dose
epirubicin 150 mg/m
2 given every 3 weeks by two
different schedules produced similar response rates
(14± 15%) to standard-dose doxorubicin 75 mg/m
2
every 3 weeks (14%), with no difference in overall
survival (p=0.89). In one randomized study from
Figure1.Meta-analysis results for objective tumour response (complete and partial).Results are expressedas an OR,which is the odds
of an event occurring in the experimental group (combination therapy) over the odds of an event occurring in the control group
(single-agent therapy).Horizontal lines denote 95% CI.Circles represent point estimates.
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24 50 patients receiving epirubicin 60 mg/m
2/
24 h on days 1,2 and 3 (group A) were compared
with 56 patients given the same dose of epirubicin +
cisplatin 30 mg/m
2/24 h on days 2± 5 (group B).The
response rate was higher for group B (54% versus
29%;p < 0.025) and so was overall survival (p=0.001).
However, median survival times were approximately
10 months versus 8 months,in the same range as the
median survival times in studies shown in Table 2.
Adding this study to the meta-analyses did not
signi® cantly alter the outcomes for responserate (OR,
0.74; 95% CI, 0.55± 1.00; p=0.051) or survival (OR,
0.78; 95% CI, 0.60± 1.03; p=0.078). In view of the
very limited data on epirubicin, the conclusions and
practice guideline are based on the doxorubicin
studies.
Adverse effects
Reportingof adverse effects was quite variable among
the eight eligible trials. Most of the studies reported
nausea/vomiting and haematologic toxic effects. As
all these studieswere performedbeforethe widespread
use of 5-HT3 receptor antagonists, nausea and
vomiting were reported frequently. As can be seen
fromTable 3, with the exception of the studyreported
by Borden et al.,
7 nausea and vomiting were always
greater for combination regimens, often signi® cantly
so.Similarly,haematologictoxic effects were reported
in different ways among studies. Leucopenia and
thrombocytopenia were reported sometimes
separately, sometimes in combination. In many of
these studies, nadir blood counts were not neces-
sarily performed and there may be under-reporting
of haematologic toxicity. Again, it is evident from
Table 3 that the haematologic toxicity of combina-
tion chemotherapy was always higher than that of
single-agent doxorubicin.Neutropenic fever was not
reported consistently;neither were other toxic effects,
such as mucositis. Although the more recent studies
did report toxic deaths,
6± 9 these were uncommon
across all the studies.Reporting of cardiotoxicity was
highly variable and it was impossible to determine
whether this was worse for single-agent or combina-
tion regimens; ultimately, it depended on the
individual dose of doxorubicin received by each
patient. Quality of life was not addressed in any of
the studies included in this report.
Practitioner feedback results
Fifty-three practitioners in Ontario, Canada, were
surveyed. The sample consisted of medical oncolo-
gists, radiation oncologists, surgeons, gynaecologists
and pharmacists. Of the respondents, 76% agreed
with the recommendations and 72% approved the
recommendations as a practice guideline. Fifty per
cent of the respondents provided written comments.
These comments were reviewed by the members of
the Sarcoma DSG, and modi® cations were made to
the document, where necessary, to address the
comments.
There was a request for acknowledgementof trials
usingepirubicinalone or in combination in the pallia-
tive setting. A search was performed, and a rand-
omized trial was added to the meta-analysis.
24There
was also a query regardingthe correlation of response
to chemotherapywith histologicalsubtype of sarcoma.
A paragraph was added to the `Discussion’ section to
addressthis comment.One practitioner stated a belief
that a regimen with a 30% response rate would
providea signi® cant palliative bene® t to morepatients
than a regimen that produced an 18% response rate.
The members of the Sarcoma DSG felt that there
was no evidencefor this statement,as palliative benefit
dependsnotonlyon responserate,but also on toxicity.
No changeswere made to the document.Somephysi-
cians suggested reviewing data on other agents or
Figure 2. Meta-analysis results for survival (at 2 years).Results are expressed as an OR, which is the odds of an event occurring in
the experimental group (combination therapy) over the odds of an event occurring in the control group (single-agent therapy).
Horizontal lines denote 95% CI.Circles represent point estimates.
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managementof soft-tissue sarcoma.That was not the
focus of this guideline. Consequently, no changes
were made to address this comment.
Discussion
Response rates for combination chemotherapy were
signi® cantly better than for single-agent doxorubicin
in only two of the eight randomized trials. Pooling of
response data showed a slight trend favouring
combinationchemotherapy(OR,0.79;95% CI,0.60±
1.05), but this did not achieve statistical signi® cance
(p=0.10). Similarly, combining survival data did not
show a signi® cant difference between treatment
groups (OR, 0.84; 95% CI, 0.67± 1.06; p=0.13).
Although reporting of adverse effects was limited and
inconsistentamong trials (making pooling of data for
this outcomeproblematic),side-effectssuchas nausea/
vomiting and haematologictoxic effects were consist-
ently reported as being worse with combination
chemotherapy across the eight eligible studies.
A number of authors have suggested that response
to chemotherapy may vary with histological subtype,
although there are discrepancies between studies in
identifying the most and least responsive histologies.
Potential ¯ aws of these studies include insufficient
patient numbers for reliable statistical analysis and
variability in pathological interpretation. The most
extensive database, which has been subjected to
central histopathological review,has been established
by the EORTCSoftTissueand BoneSarcomaGroup.
Van Glabbeke et al. reported on 2185 patients with
advanced soft-tissue sarcoma treated in seven clinical
trials investigating the useof anthracycline-containing
regimens as ® rst-line chemotherapy.
25 Univariate
analysis showed increased survival times for patients
with liposarcoma and synovial sarcoma, decreased
survival times for patients with malignant ® brous
histiocytoma and a higher response rate for patients
with liposarcoma (p<0.05 for all log-rank and c 2
tests). However, using multivariate analysis, the only
signi® cant in¯ uence of pathological subtype
documented was that a diagnosis of liposarcoma was
a favourable prognostic factor for response rate
(p=0.006 5).
The main limitation of the present review is the
fact that a number of different doxorubicin-based
combination chemotherapy regimens have been
compared with doxorubicin.Fourof the eight studies
compared combinations which included drugs
considered to have limited activity as single-agent
regimens in advanced soft-tissue sarcoma (i.e. vinc-
ristine,vindesine,cyclophosphamide,streptozotocin,
mitomycin-C, cisplatin). However, even the four
studies which used the known active agents in
combination with doxorubicin (i.e. ifosfamide and
DTIC) produced mixed results.Thus, the response
rate for doxorubicin/DTIC was better than that for
doxorubicin in one study,
6 and similar in another
study.
4Also,for doxorubicin/ifosfamide,the response
rate was better than for doxorubicin alone in the
study reported by Edmonson et al.,
8 but similar in
the EORTC study reported by Santoroet al.
9A meta-
analysis of these four trials did not demonstrate a
signi® cant difference in response rate (p=0.15).The
three-drug combination of doxorubicin, DTIC and
ifosfamide has never been directly compared with
doxorubicin alone. However, in a recent randomized
study, a superior response rate was shown for the
three-drugcombination doxorubicin,DTIC and ifos-
famide compared with the combination of doxoru-
bicin and DTIC (32% versus 17%; p<0.002) but
with increased myelosuppression and no improve-
ment in overall survival.
26 Since the publication of
these studies, no new active drugs have been identi-
® ed in soft-tissue sarcoma.
In virtually all of the reviewed studies, the toxic
effects of combination chemotherapy (particularly
nauseaand vomiting and myelosuppression)exceeded
those of single-agent doxorubicin. It can be argued
that modern anti-emetics and growth factor support
might reduce or eliminate these differences, but in
the setting of palliative chemotherapy, the costs of
such strategies (particularly with granulocyte colony-
stimulating factor) must be weighed against the
expected bene® ts.
In the reviewedstudies,633 of 1086 patients (58%)
receiving doxorubicin were given a dose of
70± 75 mg/m
2 every 3 weeks.Toxicity data from these
studies were too sparse to provide an EBR regarding
dose.However,the EORTC has extensive experience
of the safety and efficacy of doxorubicin 75 mg/m
2
every 3 weeks,
9,22,27 and this dose schedule is
commonly used by sarcoma specialists throughout
North America and Canada.Thus, for the palliative
treatment of symptomatic locally advanced or
metastatic soft-tissue sarcoma,an appropriate starting
dose schedule of doxorubicin is 75 mg/m
2
intravenously every 3 weeks.
In summary, combinations of the known active
drugs used at conventional doses can produce
marginal increases in response rate in advanced/
metastatic soft-tissue sarcoma, at the expense of
increased adverse effects, but do not signi® cantly
increasesurvival rates.Thus,the results of this analysis
favour the use of single-agent doxorubicin for pallia-
tive treatment of advanced/metastatic soft-tissue
sarcoma.
Practice guideline
This recommendation applies to patients with
symptomatic unresectable locally advanced or
metastatic soft-tissue sarcoma who are candidates for
palliative chemotherapy.
· Single-agent doxorubicin is an appropriate ® rst-
line chemotherapy option for advanced or
metastatic soft-tissue sarcoma. Some doxorubicin-
based combination chemotherapy regimens, given
110 V .H.C.Bramwell et al.in conventional doses, produce only marginal
increases in response rates, at the expense of
increased toxic effects, and with no improvements
in overall survival.
· Future randomized clinical trials should compare
new regimens, whose activity has been established
in single-arm studies, with single-agent doxoru-
bicin, and include quality of life as an outcome
measure.
Practice guideline date
Completed 30 November 1999. Updated 28 January
2000.
Cancer Care Ontario Practice Guidelines Initiative
(CCOPGI) practice guidelines are reviewed and updated
regularly. Please visit the CCOPGI website at http://
www.cancercare.on.ca/ccopgi/for updates to thisguideline.
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